Safety and Pharmacokinetics of Ppi-461, a Potent New Hepatitis C Virus (Hcv) Ns5a Inhibitor with Pan-Genotype Activity

Trial Profile

Safety and Pharmacokinetics of Ppi-461, a Potent New Hepatitis C Virus (Hcv) Ns5a Inhibitor with Pan-Genotype Activity

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2010

At a glance

  • Drugs PPI 461 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 27 Oct 2010 Results from this trial will be presented at the American Association for the Study of Liver Diseases (AASLD) according to a Presidio Pharmaceuticals media release.
    • 14 Jul 2010 Status changed from recruiting to completed, according to a Presidio Pharmaceuticals media release.
    • 14 Jul 2010 Results reported in a Presidio Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top